Nipro Stock - analyst consensus and strategy snapshot

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 15:17 UTC. Details in the imprint.

Nipro (JP3563400006) enters mid-week without a fresh market-moving announcement from its investor relations team or the major newswires. The stock nevertheless remains anchored by published analyst estimates and the group’s steady medical-device strategy.

What recent numbers show

In its most recent full-year results for the fiscal year ended 03/31/2025, Nipro reported consolidated revenue in the mid- to high-hundreds of billions of yen and continued to emphasize growth in medical devices and pharma packaging, according to its English-language annual materials.

The company highlighted stable demand for dialysis-related products and blood tubing sets, alongside growth in prefilled syringes and other injection systems for pharmaceutical customers in Japan and overseas, based on the latest available presentation to investors.

Analyst views and consensus tone

Sell-side coverage of Nipro on Tokyo tends to be moderate in scope, with a handful of Japanese brokerages publishing target prices and earnings projections clustered around the company’s medium-term plan, as aggregated on common financial data platforms.

Across those sources, the tone toward Nipro stock is generally neutral to cautiously constructive, with expectations of incremental revenue growth and margin improvement rather than aggressive expansion, in line with the firm’s positioning as a diversified medical supplier.

How the company makes money

Nipro generates most of its revenue from medical devices, including dialysis-related disposables and machines, injection and infusion products, and cardiovascular devices, complemented by a pharmaceutical segment that supplies glass vials, ampoules and prefilled syringes for drug manufacturers.

Where the stock trades today

Nipro shares trade on the Tokyo Stock Exchange in Japanese yen; a specific up-to-the-minute quote could not be reliably verified at the time of editing.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.